Enhanced Monitoring for Better Recovery and Cancer Experience in GM

• Research type

  Research Study

• Full title

  Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester - EMBRaCE-GM

• IRAS ID

  294391

• Contact name

  Anthony Wilson

• Contact email

  anthony.wilson@mft.nhs.uk

• Sponsor organisation

  Manchester University NHS Foundation Trust

• Duration of Study in the UK

  1 years, 3 months, 31 days

• Research summary

  The EMBRaCE-GM study is a multi-cohort trial designed to efficiently evaluate the range of wearable vital signs monitors that could be used to support patients during cancer treatment.

  The aims of the study are to determine
  - to determine if continuous vital signs monitoring is feasible during cancer treatment
  - to determine if such monitoring is acceptable to patients undergoing cancer treatment
  - to determine what insights could be made with the data obtained

  A multi-cohort study is essential because there are a huge range of vital signs monitors that could be useful and we need a method that allows us to quickly identify the devices that are most acceptable to patients and which offer the most useful information to clinicians. Similarly, the best device may vary according to the specific disease and the treatment a patient is offered.
  Each cohort in the study will investigate a variety of wearable vital signs monitors in different patient groups undergoing different treatments. A common data collection platform will be used for all cohorts with a modular design that allows data collection to be adapted slightly to meet specific needs for each cohort.

• REC name

  Wales REC 6

• REC reference

  21/WA/0251

• Date of REC Opinion

  6 Sep 2021

• REC opinion

  Further Information Favourable Opinion